Section 4.2 of the SPCs for Xatral XL and Xatral have been updated to include that the efficacy of alfuzosin has not been demonstrated in children aged 2 to 16 years, and it is therefore not indicated for use in the paediatric population.
Please see below for link to SPCs and full prescribing information.l